{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:03Z","timestamp":1791828543668,"version":"4.3.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ek01099464s0403"],"award-info":[{"award-number":["22ek01099464s0403"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>21-hydroxylase deficiency (21-OHD) is the most common form of congenital adrenal hyperplasia. In most developed countries, newborn screening enables diagnosis of 21-OHD in asymptomatic patients during the neonatal period. In addition, recent advances in genetic testing have facilitated diagnosing 21-OHD, particularly in patients with equivocal clinical information. On the other hand, many challenges related to treatment remain. The goals of glucocorticoid therapy for childhood 21-OHD are to maintain growth and maturation as in healthy children by compensating for cortisol deficiency and suppressing excess adrenal androgen production. It is not easy to calibrate the glucocorticoid dosage accurately for patients with 21-OHD. Auxological data, such as height, body weight, and bone age, are considered the gold standard for monitoring of 21-OHD, particularly in prepuberty. However, these data require months to a year to evaluate. Theoretically, biochemical monitoring using steroid metabolites allows a much shorter monitoring period (hours to days). However, there are many unsolved problems in the clinical setting. For example, many steroid metabolites are affected by the circadian rhythm and timing of medication. There is still a paucity of evidence for the utility of biochemical monitoring. In the present review, we have attempted to clarify the knowns and unknowns about treatment parameters in 21-OHD during childhood.<\/jats:p>","DOI":"10.3389\/fendo.2023.1102741","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T04:59:57Z","timestamp":1675400397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Monitoring treatment in pediatric patients with 21-hydroxylase deficiency"],"prefix":"10.3389","volume":"14","author":[{"given":"Tomoyo","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021561","article-title":"Congenital adrenal hyperplasia","volume":"349","author":"Speiser","year":"2003","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2022-0009","article-title":"Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)","volume":"31","author":"Ishii","year":"2022","journal-title":"Clin Pediatr Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0905","article-title":"Abiraterone acetate treatment lowers 11-oxygenated androgens","volume":"182","author":"Wright","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: Results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/en.2016-1455","article-title":"ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00117","article-title":"A long-acting neutralizing monoclonal ACTH antibody blocks corticosterone and adrenal gene responses in neonatal rats","volume":"160","author":"Gehrand","year":"2019","journal-title":"Endocrinology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"A350","DOI":"10.1210\/jendso\/bvaa046.690","article-title":"MON-176 discovery and identification of late stage selective nonpeptide ACTH antagonists for the treatment of cushing\u2019s disease, ectopic ACTH secreting tumors, and congenital adrenal hyperplasia","volume":"4","author":"Kusnetzow","year":"2020","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"A354","DOI":"10.1210\/jendso\/bvaa046.699","article-title":"OR19-03 effects of nonpeptide orally bioavailable ACTH antagonists on adrenal gland size and function in rats","volume":"4","author":"Markison","year":"2020","journal-title":"J Endocr Soc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1067\/mpd.2001.110527","article-title":"Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A meta-analysis","volume":"138","author":"Eugster","year":"2001","journal-title":"J Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: Adult height in patients with congenital adrenal hyperplasia: A systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0942","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation","volume":"94","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000322580","article-title":"Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life","volume":"75","author":"Bonfig","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1486","article-title":"Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United kingdom congenital adrenal hyperplasia adult study executive (CaHASE)","volume":"99","author":"Han","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.11.027","article-title":"The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia","volume":"166","author":"Bomberg","year":"2015","journal-title":"J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2016-0156","article-title":"Growth curves for congenital adrenal hyperplasia from a national retrospective cohort","volume":"29","author":"Bretones","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4103\/ijem.IJEM_99_19","article-title":"Clinical patterns and linear growth in children with congenital adrenal hyperplasia, an 11-year experience","volume":"23","author":"Al Shaikh","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab701","article-title":"Characteristics of growth in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency during adrenarche and beyond","volume":"107","author":"Troger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01645.x","article-title":"Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome","volume":"57","author":"Manoli","year":"2002","journal-title":"Clin Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.64.9.1235","article-title":"Monitoring treatment in congenital adrenal hyperplasia","volume":"64","author":"Appan","year":"1989","journal-title":"Arch Dis Child"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.76.4.8473408","article-title":"Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency","volume":"76","author":"Helleday","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1651-2227.1993.tb12844.x","article-title":"Temporal and individual variations in the dose of glucocorticoid used for the treatment of salt-losing congenital virilizing adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"388","author":"Sandrini","year":"1993","journal-title":"Acta Paediatr Suppl"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.12.4473","article-title":"Steroid therapy for adrenal disorders\u2013getting the dose right","volume":"82","author":"Kleerekoper","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0889-8529(08)70026-4","article-title":"Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. growth, development, and therapeutic considerations","volume":"30","author":"Migeon","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000333696","article-title":"Adrenarche and puberty in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"76","author":"Volkl","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12033","article-title":"Prevalence and long-term follow-up outcomes of testicular adrenal rest tumours in children and adolescent males with congenital adrenal hyperplasia","volume":"78","author":"Aycan","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000365570","article-title":"Increased prevalence of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia","volume":"82","author":"Claahsen-van der Grinten","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12098-018-02848-6","article-title":"Growth pattern and clinical profile of Indian children with classical 21-hydroxylase deficiency congenital adrenal hyperplasia on treatment","volume":"86","author":"Meena","year":"2019","journal-title":"Indian J Pediatr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-4-200202190-00012","article-title":"NIH Conference. future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"136","author":"Merke","year":"2002","journal-title":"Ann Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1297\/cpe.24.77","article-title":"Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)","volume":"24","author":"Ishii","year":"2015","journal-title":"Clin Pediatr Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012517.pub2","article-title":"Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia","volume":"3","author":"Ng","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1249","article-title":"International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry","volume":"184","author":"Bacila","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B38","article-title":"Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"6","author":"Einaudi","year":"1993","journal-title":"J Pediatr Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000129677","article-title":"Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: The Leipzig experience","volume":"70","author":"Hoepffner","year":"2008","journal-title":"Horm Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1297\/cpe.6.57","article-title":"Hormonal regulation of growth and maturation: I. the effect of hormones on fetal growth","volume":"6","author":"Hibi","year":"1997","journal-title":"Clin Pediatr Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3989","article-title":"11-oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency","volume":"102","author":"Turcu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa192","article-title":"11-oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency","volume":"5","author":"Jha","year":"2021","journal-title":"J Endocr Soc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7972","article-title":"Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory","volume":"86","author":"Charmandari","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0064","article-title":"Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers","volume":"173","author":"Debono","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-022-00354-1","article-title":"The utility of annual growth velocity standard deviation scores and measurements of biochemical parameters in long-term treatment monitoring of children with 21-hydroxylase deficiency","volume":"21","author":"Ozdemir Dilek","year":"2022","journal-title":"Horm (Athens)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(99)70413-0","article-title":"Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples","volume":"134","author":"Bode","year":"1999","journal-title":"J Pediatr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000315910","article-title":"Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia","volume":"75","author":"Sarafoglou","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2014-0303","article-title":"Therapy monitoring in congenital adrenal hyperplasia by dried blood samples","volume":"28","author":"Wieacker","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2016-0203","article-title":"Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia","volume":"30","author":"Birkebaek","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/000456328702400109","article-title":"Radioimmunoassay of blood-spot 17 alpha-hydroxyprogesterone in the management of congenital adrenal hyperplasia","volume":"24","author":"Robinson","year":"1987","journal-title":"Ann Clin Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032235","article-title":"Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia","volume":"89","author":"Minutti","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2006.01.015","article-title":"Automated, fast and sensitive quantification of 17 alpha-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line extraction","volume":"71","author":"Rauh","year":"2006","journal-title":"Steroids"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2011.07.013","article-title":"Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry","volume":"76","author":"Janzen","year":"2011","journal-title":"Steroids"},{"key":"B55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1297\/cpe.16.45","article-title":"Pregnanetriol in the range of 1.2-2.1 mg\/m(2)\/day as an index of optimal control in CYP21A2 deficiency","volume":"16","author":"Izawa","year":"2007","journal-title":"Clin Pediatr Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1297\/cpe.17.75","article-title":"The range of 2.2-3.3 mg\/gCr of pregnanetriol in the first morning urine sample as an index of optimal control in CYP21 deficiency","volume":"17","author":"Izawa","year":"2008","journal-title":"Clin Pediatr Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00438","article-title":"Height velocity defined metabolic control in children with congenital adrenal hyperplasia using urinary GC-MS analysis","volume":"104","author":"Kamrath","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2000.13.2.205","article-title":"Correlation of blood-spot 17-hydroxyprogesterone daily profiles and urinary steroid profiles in congenital adrenal hyperplasia","volume":"13","author":"Erhardt","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.808254","article-title":"First morning pregnanetriol and 17-hydroxyprogesterone correlated significantly in 21-hydroxylase deficiency","volume":"12","author":"Itonaga","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154354","article-title":"Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia","volume":"112","author":"Kamrath","year":"2020","journal-title":"Metabolism"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105553","article-title":"Urinary steroidomic profiles by LC-MS\/MS to monitor classic 21-hydroxylase deficiency","volume":"198","author":"Pussard","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0006","article-title":"Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty","volume":"32","author":"Pijnenburg-Kleizen","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2012.02584.x","article-title":"Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period","volume":"48","author":"Shetty","year":"2012","journal-title":"J Paediatr Child Health"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz006","article-title":"Increased infection risk in addison\u2019s disease and congenital adrenal hyperplasia","volume":"105","author":"Tresoldi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa801","article-title":"Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: A population-based cohort study","volume":"106","author":"Hirschberg","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1102741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T14:05:47Z","timestamp":1675865147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1102741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":65,"alternative-id":["10.3389\/fendo.2023.1102741"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1102741","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1102741"}}